Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 May 21;6(4):e577.
doi: 10.1212/NXI.0000000000000577. eCollection 2019 Jul.

Immunotherapy improves sleep and cognitive impairment in anti-IgLON5 encephalopathy

Valerio Brunetti  1 , Giacomo Della Marca  1 , Gregorio Spagni  1 , Raffaele Iorio  1
Affiliations
Case Reports

Immunotherapy improves sleep and cognitive impairment in anti-IgLON5 encephalopathy

Valerio Brunetti et al. Neurol Neuroimmunol Neuroinflamm. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure. Hypnogram and density spectral array images
(A) Hypnogram and DSA before the treatment. Hypnogram: undifferentiated NREM sleep is prevalent, particularly at the sleep onset and in the second half of the night (black arrows); REM sleep is not detectable. DSA showing the power spectrum of electroencephalographic frequencies (0–64 Hz) in bipolar C3-O1 derivation: undifferentiated NREM sleep is characterized by a continuous activity with a double peak of frequency at 5 and 10 Hz. (B) Hypnogram and DSA after 1 year of immunotherapy. Hypnogram: an NREM-REM cycle is present. Undifferentiated NREM sleep is still present in the second half of the night (black arrow). DSA: undifferentiated NREM sleep is still characterized by a continuous activity with a double peak of frequency at 5 and 10 Hz. DSA = density spectral array.
See this image and copyright information in PMC

References

    1. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014;13:575–586. - PMC - PubMed
    1. Iorio R, Damato V, Evoli A, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 2018;89:138–146. - PubMed
    1. Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016;132:531–543. - PMC - PubMed
    1. Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of wakefulness and sleep. Neuron 2017;93:747–765. - PMC - PubMed
    1. Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation 2016;13:226. - PMC - PubMed

Publication types